Program
fazamorexant
Also written as “YZJ-1139”, “YZJ-1139 tablets” and “YZJ-1139 20mg”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders, led by Shanghai Haiyan Pharmaceutical Technology.
Furthest: phase 3, since Aug 24, 20229 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Haiyan Pharmaceutical Technology | 90 open or running | phase 3since Aug 24, 2022 | Aug 24, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2022First study: phase 3 study in Sleep Initiation and Maintenance DisordersFirst studyNCT05525637 · 1,037 enrolled · China
- Oct 31, 20243 phase 1 studies in Sleep Initiation and Maintenance DisordersNCT06680531, NCT06671470, NCT06671444
- Nov 1, 2024Phase 2 study in Sleep Initiation and Maintenance DisordersNCT06680505 · 300 enrolled · China
- Nov 1, 20243 phase 1 studies in Sleep Initiation and Maintenance DisordersNCT06673927, NCT06671509, NCT06685341
- May 9, 2025Phase 3 study in Sleep Initiation and Maintenance DisordersNCT06975514 · 61 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06975514Sleep Initiation and Maintenance Disorders · China | 3 | Completed | Jul 21, 2025 | 61 |
| NCT06685341Sleep Initiation and Maintenance Disorders · China | 1 | Completed | Apr 10, 2019 | 20 |
| NCT06680505Sleep Initiation and Maintenance Disorders · China | 2 | Completed | Sep 30, 2020 | 300 |
| NCT06673927Sleep Initiation and Maintenance Disorders · China | 1 | Completed | Nov 21, 2018 | 104 |
| NCT06671509Sleep Initiation and Maintenance Disorders · China | 1 | Completed | Apr 18, 2024 | 24 |
| NCT06680531Sleep Initiation and Maintenance Disorders · China | 1 | Completed | Sep 19, 2024 | 24 |
| NCT06671470Sleep Initiation and Maintenance Disorders · China | 1 | Completed | Sep 13, 2024 | 27 |
| NCT06671444Sleep Initiation and Maintenance Disorders · China | 1 | Completed | Oct 11, 2024 | 16 |
| NCT05525637Sleep Initiation and Maintenance Disorders · China | 3 | Completed | Jul 7, 2023 | 1,037 |
How it is read
Names in the registry
- “YZJ-1139”, 6 entries
- “YZJ-1139 tablets”, 2 entries
- “YZJ-1139 20mg”, 2 entries
- “YZJ-1139 40mg”, 2 entries
- “YZJ-1139 simulated tablets”, 1 entry
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.